Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84129 | 0.82 | — | — | |
| SCHEMBL24391215 | 0.72 | ALOX5 (0.38) | ALOX5ALDH1A1HTR2A | |
| SCHEMBL22702324 | 0.72 | ALOX5 (0.38) | ALOX5ALDH1A1HTR2A | |
| SCHEMBL11886637 | 0.69 | BRD4 (0.35) | MAPTBRD4 | |
| SCHEMBL11886628 | 0.69 | BRD4 (0.35) | MAPTBRD4 | |
| SCHEMBL22560049 | 0.67 | — | — | |
| SCHEMBL18196372 | 0.66 | BRD4 (0.35) | ALOX5BRD4CREBBP | |
| SCHEMBL28245587 | 0.65 | ALOX5 (0.37) | ALOX5ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL11886634 | 0.65 | BRD4 (0.35) | ALOX5BRD4 | |
| SCHEMBL21669887 | 0.64 | ALOX5 (0.42) | ALOX5MAPTBRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983402-B1 | 1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | PHARVARIS GMBH (CH) | 2023-08-16 | — | — | EP | disclosed |
| US-20120189623-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120189623-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | CYP3A5, GDI2, HDAC5 | ALOX5 879/4885ADORA3 2566/4885ADORA2A 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.